Chemours (CC) Tops Q4 EPS by 6c, FY EPS Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
The Chemours Company Reports Fourth Quarter and Full Year 2018 Results
February 14, 2019 4:15 PM ESTWILMINGTON, Del., Feb. 14, 2019 /PRNewswire/ --
Full Year 2018 Highlights
Net Sales of $6.6 billion, up 7% Net Income of $995 million, up 33%, with EPS of $5.45, up 39% Adjusted Net Income of $1.0 billion, up 42%, with Adjusted EPS of $5.67, up 48% Adjusted EBITDA of $1.7 billion, up 22% Returned over $790 million to shareholders through share repurchases and dividendsFourth Quarter 2018 Highlights
Net Sales of $1.5 billion Net Income of $142 million with EPS of $0.81 Adjusted Net Income of $185 million, with Adjusted EPS of $1.05 Adjusted EBITDA of $341 millionOther... More

